Feasibility study of postoperative adjuvant chemotherapy with S-1 (tegaful, gimeracil, oteracil potassium) for non-small cell lung cancer-LOGIK 0601 study

Lung Cancer

Volumn 67, Issue 2, 2010, Pages 184-187

  Yano, Tokujiro ^a   Yamazaki, Koji ^b   Maruyama, Riichiroh ^c   Tokunaga, Shoji ^a   Shoji, Fumihiro ^a   Higashi, Hidefumi ^c   Takeo, Sadanori ^d   Ichinose, Yukito ^b   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c STEEL MEMORIAL YAWATA HOSPITAL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

Author keywords

5 Fluorouracil; Dihydropyrimidine dehydrogenase (DPD); Elderly patients; Feasibility study; Non small cell lung cancer; Outpatient; Renal impairment; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR;

ADULT; AGE; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SURGERY; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DIGESTIVE SYSTEM HEMORRHAGE; DIZZINESS; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEASIBILITY STUDY; FEMALE; HEMATOLOGIC DISEASE; HEMATURIA; HUMAN; HYPERGLYCEMIA; KIDNEY DISEASE; LONG TERM CARE; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PATIENT COMPLIANCE; POSTOPERATIVE CARE; PRIORITY JOURNAL; RECURRENT CANCER; THROMBOCYTOPENIA;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DRUG COMBINATIONS; FEASIBILITY STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; TEGAFUR;

EID: 72449210496     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.03.028     Document Type: Article

References (14)

1. Mountain C.F. Revisions in international staging system for lung cancer. Chest 111 (1997) 1710-1717
2. Goya T., Asamura H., Yoshimura H., Kato H., Shimokata K., Tsuchiya R., et al. Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer 50 (2005) 227-234
3. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351-360
4. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell-lung cancer. N Engl J Med 352 25 (2005) 2589-2597
5. Douillard J.Y., Rosell R., De Lena M., Carpagnano F., Ramlau R., Gonzales-Larriba J.L., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomized controlled trial. Lancet Oncol 7 (2006) 719-727
6. Kawahara M., Furuse K., Segawa Y., Yoshimori K., Matsui K., Kudoh S., et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 85 (2001) 939-943
7. Green S., and Dahlberg S. Planned versus attained design in phase II clinical trials. Stat Med 11 (1992) 853-862
8. Sakuramoto S., Sasako M., Yamaguchi T., Kinoshita T., Fujii M., Nashimoto A., et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357 (2007) 1810-1820
9. Kinoshita T., Nashimoto A., Yamamura Y., Okamura T., Sasako M., Sakamoto J., et al. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer. Gastric Cancer 7 (2004) 104-109
10. Tsukuda M., Kida A., Fujii M., Kono N., Yoshihara T., Hasegawa Y., et al. Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer. Br J Cancer 93 (2005) 884-889
11. Ikeda M., Furukawa H., Imamura H., Shimizu J., Ishida H., Masutani S., et al. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. Cancer Chemother Pharmacol 50 (2002) 25-32
12. Kato H., Ichinose Y., Ohta M., Hata E., Tsubota N., Tada H., et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350 (2004) 1713-1721
13. Hamada C., Tanaka F., Ohta M., Fujimura S., Kodama K., Imaizumi M., et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 23 (2005) 4999-5006
14. Wada H., Hitomi S., Teramatsu T., and the West Japan Study Group for Lung Cancer Surgery. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. J Clin Oncol 14 (1996) 1048-1054